Ratings Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Market Closed - Swiss Exchange Other stock markets 11:31:57 2024-04-25 am EDT			5-day change	1st Jan Change
40.25 ^CHF	-0.74%		-4.05%	+14.02%

Apr. 09	Basilea Pharmaceutica Receives Grant for Antibiotics Program	MT
Apr. 04	Stocks Close in Green as Swiss Inflation Unexpectedly Slows	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's profit outlook over the next few years is a strong asset.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BASILEA PHARMACEUTICA AG	+14.02%	533M	C+
IQVIA HOLDINGS INC.	+0.61%	43.84B	B
MODERNA, INC.	+5.25%	41.68B	B-
LONZA GROUP AG	+45.26%	41.25B	A
CELLTRION, INC.	-11.96%	27.04B	C
ICON PUBLIC LIMITED COMPANY	+6.58%	25.53B	B-
ALNYLAM PHARMACEUTICALS, INC.	-25.40%	18.18B	B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.23%	12.29B	C+
MEDPACE HOLDINGS, INC.	+25.82%	12.29B	C+
UNITED THERAPEUTICS CORPORATION	+6.84%	11.15B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes